Progress in Pharmacotherapy for Obesity
Open accessAbstract
This Viewpoint discusses the potential that newer antiobesity medications can provide for greater weight loss efficacy with an acceptable safety profile, including those with novel “twincretin” mechanisms of action.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Phentermine is the most commonly prescribed antiobesity medication and is an affordable alternative to other therapies, but it has sympathomimetic effects.
“Phentermine is the most commonly prescribed antiobesity medication115 and is an affordable alternative to other therapies, but it has sympathomimetic effects.116”
From Obesity Management in Adults (2023) · cites this paper as [115]
Liraglutide 3.0 mg and phentermine-topiramate ER induce mean 1-year reductions of 8-11% of baseline weight when combined with approximately monthly lifestyle counseling.
“The last two medications are the most effective of the four, inducing mean 1-year reductions of 8–11% of baseline weight when combined with approximately monthly lifestyle counseling [37–39].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 11 · Cited by 67
- Authors
- Yanovski, S. Z., & Yanovski, J. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-07-13
- Volume
- 326
- Issue
- 2
- Pages
- 129
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8277731
- OpenAlex
- W3173578288
- Cited by
- 67
- References
- 11
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 10 · 2023: 18 · 2022: 19 · 2021: 4
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99HD999999)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD000641)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- anti-obesity drugs, pharmacotherapy, weight loss, drug safety, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, obesity treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Obesity, Clinical Trials, Phase III as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
